IRVINE, Calif., March 7, 2011 /PRNewswire/ -- Endologix, Inc.
(Nasdaq: ELGX), developer of minimally invasive treatments for
aortic disorders, announced today that John
McDermott, President and Chief Executive Officer, is
scheduled to present at the ROTH 23rd Annual OC Growth Stock
Conference in Laguna Niguel,
CA.
Event:
|
ROTH 23rd Annual OC Growth Stock
Conference
|
|
Date:
|
Monday, March 14,
2011
|
|
Time:
|
4:30 p.m. PT
|
|
|
|
An audio Web cast of the Company's presentation will be
available by visiting the investor relations section of Endologix's
Web site at www.endologix.com. A replay of the presentation
will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship product is
the Powerlink® System, which is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening
of the wall of the aorta, the largest artery in the body, resulting
in a balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix, Inc.
|
The Ruth Group
|
|
John McDermott, CEO
|
Nick Laudico (646)
536-7030
|
|
(949) 595-7200
|
Zack Kubow (646)
536-7020
|
|
www.endologix.com
|
|
|
|
|
SOURCE Endologix, Inc.